Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
|Slideshows|February 12, 2019
Research Roundup: New Developments in Lupus
Increased cancer risk, a new measure for disease outcomes and a new treatment are among the developments in systemic lupus erythematosus (SLE) published in recent months. Learn more in this slideshow.
Advertisement
Increased cancer risk, a new measure for disease outcomes and a new treatment are among the developments in systemic lupus erythematosus (SLE) published in recent months. Learn more in this slideshow.
Advertisement
Related to this article
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.
A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.
Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.
Advertisement
Advertisement